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barrier, and cerebral amyloid angiopathy has been shown to be a prominent feature in the majority of
Alzheimer's disease. Quercetin is a natural ﬂavonoid molecule and has been demonstrated to have potent
neuroprotective effects, but its protective effect on endothelial cells under Aβ-damaged condition is
unclear. In the present study, the protective effects of quercetin on brain microvascular endothelial cells
injured by ﬁbrillar Aβ1–40 (fAβ1–40) were observed. The results show that fAβ1–40-induced cytotoxicity in
human brain microvascular endothelial cells (hBMECs) can be relieved by quercetin treatment. Quercetin
increases cell viability, reduces the release of lactate dehydrogenase, and relieves nuclear condensation.
Quercetin also alleviates intracellular reactive oxygen species generation and increases superoxide
dismutase activity. Moreover, it strengthens the barrier integrity through the preservation of the
transendothelial electrical resistance value, the relief of aggravated permeability, and the increase of
characteristic enzyme levels after being exposed to fAβ1–40. In conclusion, quercetin protects hBMECs
from fAβ1–40-induced toxicity.
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Yongjie Li et al.481. Introduction
In the pathogenesis of Alzheimer's disease (AD), accumulation and
deposition of β-amyloid peptides (Aβ) in the brain plays a vital
role. Aβ is cleared from the brain across the blood–brain barrier
(BBB)1,2. In AD patients, destruction of the BBB leads to Aβ
clearance disruption, resulting in Aβ plaques and cerebral amyloid
angiopathy (CAA)3,4. The pathology of microvascular CAA is
closely related to the cerebrovascular dysfunction that contributes
to disease progression2,5. Among all the cerebral microvasculature
comorbidities in AD, cerebrovascular Aβ deposition is the most
common pathological ﬁnding, presenting in up to 90% of AD
patients. Amyloid deposition is observed at sites in the cerebro-
vasculature, mainly in the leptomeningeal and cortical vessels6,7.
Cerebrovascular amyloidosis is a central factor in AD pathogenesis
and supported by increasing evidence.
Brain microvascular endothelial cells (BMECs) contribute to
maintenance of brain homeostasis and the formation of the
BBB8. In recent studies, it was found that treatment with Aβ
could stimulate inﬂammatory responses, reduce endothelial anti-
oxidants, augment transendothelial migration, and increase the
changes in morphology in BMEC monolayers9–11. Progressive
build-up of Aβ in and around vessels induces alteration in the BBB
permeability, which chronically limits blood supply and results in
deprivation of oxygen and nutrients12,13. Accordingly, these
changes trigger a secondary cascade of metabolic events involving
generation of free radicals, oxidative stress, and release of
proteases, such as γ-glutamyl transpeptidase (γ-GT) and alkaline
phosphatase (ALP)13–15. Therefore, BMECs are considered as a
potential target in AD.
Quercetin (3,30,40,5,7-pentahydroxyﬂavone, Fig. 1), a natural
ﬂavonoid compound, is found in common foods, such as tea,
berries and apples. It exerts numerous beneﬁcial effects on human
health, including anti-inﬂammation, anti-ischemia, cardiovascular
protection and neuroprotective effects16–19. Quercetin has been
reported to pass through the BBB and slow down the progression
of degenerative diseases. Additionally, quercetin was shown to
reduce the maturation of the amyloid precursor protein in human
SH-SY5Y neuroblastoma cells19,20. Quercetin signiﬁcantly
decreased the ratio of insoluble Aβ in a mouse model of AD21.
Furthermore, studies show that quercetin acts as a novel neuro-
protectant by mitigating the increased levels of reactive oxygen
species (ROS) that can accelerate the progress of AD16,17,19.
Considering the protective properties of quercetin and its
therapeutic potential, we speculated that quercetin might have a
protective effect against Aβ-induced BBB disruption. To test our
hypothesis, we employed an in vitro BBB model of human
BMECs (hBMECs). Our study assessed the effects of ﬁbrillarFigure 1 Chemical structure of quercetin.Aβ1–40 (fAβ1–40) exposure on hBMECs with respect to changes in
cell viability, oxidative stress and the barrier function. Finally, we
investigated the protective effect of quercetin on hBMECs against
fAβ1–40-induced toxicity.2. Materials and methods
2.1. Cell culture and treatment
The hBMECs were purchased from ScienCell Research Labora-
tories (Carlsbad, USA). The hBMECs were cultured in endothelial
cell complete medium (ScienCell Research Laboratories, Carlsbad,
USA). The cells were incubated at 37 1C in an atmosphere
consisting of 95% air and 5% CO2 in a humidiﬁed incubator until
reaching 80% conﬂuency.
Synthetic Aβ1–40 was purchased from Sangon Biotech Com-
pany (Shanghai, China) and dissolved in water to make a stock
solution of 0.1 mmol/L to foster the ﬁbrillization state. Quercetin
(purity498%) was purchased from Huike Botanical Development
Company (Shanxi, China). It was ﬁrst dissolved in DMSO at
100 mmol/L, and then diluted in endothelial cell medium at
30.0 μmol/L, 3.0 μmol/L and 0.3 μmol/L. Different concentrations
of quercetin were added to the cells at the start of fAβ1–40 injury,
and incubated with/without fAβ1–40 for 24 h. The cells were
randomly divided into eight groups: (1) control group; control
groups in the presence of quercetin at (2) 0.3 μmol/L, (3) 3.0 μmol/L,
(4) 30.0 μmol/L for 24 h; (5) fAβ1–40 group treated with 20 μmol/L
fAβ1–40 for 24 h; fAβ1–40 groups treated with quercetin (6)
0.3 μmol/L, (7) 3.0 μmol/L, (8) 30.0 μmol/L for 24 h.
2.2. Cell viability assay
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)2H-tetrazolium, inner salt] assay (Promega,
Madison, USA) was used for evaluating cell viability. After being
treated with quercetin and fAβ1–40 as described above, the medium
was discarded and replaced with 100 μL of MTS solution
according to the manufacturer's protocol. Then the absorbance of
samples at 490 nm was read using a SpectraMax Plus microplate
reader (Molecular Devices Corp, Sunnyvale, USA).
2.3. Lactate dehydrogenase (LDH) release assay
LDH, a soluble cytosolic enzyme present in the most eukaryotic
cells, is released into the culture medium upon cell death due to
damage to the plasma membrane. The increase in LDH activity in
the culture supernatant is proportional to the number of lysed cells.
The amount of LDH released by cells was determined using an
LDH assay kit (Promega, Madision, USA) according to manufac-
turer's protocol. Brieﬂy, after cells were exposed to fAβ1–40,
quercetin or both for 24 h, the supernatant in each well was
transferred to a new plate for LDH assay and measured in
SpectraMax Plus microplate reader.
2.4. Hoechst 33342 staining assay
Nuclear changes were measured in hBMECs using Hoechst 33342
staining (Dojindo Laboratory, Kumamoto, Japan). After the cells
were treated with fAβ1–40, quercetin, or both for 24 h, they were
washed in phosphate-buffered solution (PBS), ﬁxed in 4%
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30 min. Nuclear change was assessed by the value of average
ﬂuorescent intensity measured with a Cellomics ArrayScan VTI
HCS Reader (Cellomics Inc, Pittsburgh, USA).
2.5. Measurements of intracellular ROS and superoxide
dismutase (SOD)
The intracellular ROS level was measured using 2,7-dichloro-
ﬂuorescein diacetate (DCFH2-DA, Sigma, St. Louis, USA). After
treatment, hBMECs were washed with PBS and incubated with
DCFH2-DA at a ﬁnal concentration of 5 μmol/L for 40 min at
37 1C protected from light. The cells were then washed with PBS
to remove the extracellular DCFH2-DA, and the ﬂuorescence
intensity was measured with SpectraMax Plus microplate reader at
an excitation wavelength of 485 nm and an emission wavelength
of 538 nm. The intracellular ROS levels were expressed as
ﬂuorescent intensity. After the exposure to fAβ1–40, and quercetin,
hBMECs were collected and lysedby sonication (60 W with 0.5 s
interval for 10 min). The lysate of hBMECs was centrifuged at
10,000 g for 15 min and the supernatant fraction was used to
measure the SOD activity using WST-1 based SOD inhibition kit
(Dojindo Laboratory, Kumamoto, Japan) according to the manu-
facturer's protocols. The absorbance of the endpoint reaction at
440 nm was measured. Percent inhibition of samples was calcu-
lated by the following equation:
Inhibition %ð Þ ¼ ðA1A3ÞðASA2ÞðA1A3Þ
 100% ð1Þ
where A1, A2, A3 and AS were the absorbances of uninhibited test,
blank sample, blank reagent and sample, respectively.
2.6. Transendothelial electrical resistance (TEER)
TEER was measured using an EVOM resistance meter (World
Precision Instruments, Sarasota, USA). The extracellular matrix-
treated Transwell inserts (Corning Co., Corning, USA) were
placed in a 12-well plate containing culture medium and used to
measure the background resistance. The resistance measurements
of these blank ﬁlters were then subtracted from those of ﬁlters with
cells. TEER values were expressed as Ω  cm cm2 based on culture
inserts.
2.7. Transendotheial permeability for sodium ﬂuorescein and
FITC-labeled albumin
To measure transendotheial permeability, the extracellular matrix-
treated Transwell inserts were placed in a 12-well plate. The ﬂux
of sodium ﬂuorescein (MW, 376 Da) and ﬂuorescein isothioyanate
(FITC)-labeled albumin (MW, 67 kDa) across endothelial mono-
layers were determined as previously reported22,23. The basolateral
compartments of 12-wells contained 1.5 mL Ringer solution
(118 mmol/L NaCl, 4.8 mmol/L KCl, 2.5 mmol/L CaCl2,
1.2 mmol/L MgSO4, 5.5 mmol/L glucose, 20 mmol/L Hepes, pH
7.4). In the apical chamber, culture medium was replaced by
500 μL Ringer's solution containing 10 μg/mL sodium ﬂuorescein
and 165 μg/mL FITC-BSA. The inserts were transferred to a new
well containing Ringer's solution at 20 min, 40 min and 60 min.
FITC and ﬂuorescein levels were measured by microplate reader
(Molecular Devices Corp, Sunnyvale, USA) with emission at
488 nm, excitation at 535 nm and emission at 525 nm, excitationat 440 nm. Flux across cell-free and cell-containing inserts were
both measured. Transport was expressed as μL of donor (luminal)
compartment volume from which the tracer is completely cleared.
The transendothelial permeability coefﬁcient (Pe) was calculated
as previously described23,24. FITC-BSA concentrations in the
basolateral chamber, [BSA]basolateral, were determined from a
calibration curve of the ﬂuorescence signal, which was linearly
dependent upon BSA concentration.
Permeability, P, was calculated according to a linear approx-
imation of Fick's Law:
PS¼ J½BSA0;aptical½BSA0;basolateral
ð2Þ
where S is the surface area of the transwell insert and [BSA]0,apical and
[BSA]0,basolateral are the initial concentration of FITC-BSA in the
top and bottom chamber, respectively. The ﬂux, J, was calculated
as the product of the volume of the basolateral chamber times the
rate of increase in basolateral FITC-BSA concentration determined
from the linear region of [BSA]basolateral versus time plot. Perme-
ability was measured for each experimental group of endothelial
monolayers, as well as for membrane supports in the absence of
monolayers. Diffusional Pe were calculated by correction for the
permeability of the membrane support in series with the mono-
layer:
1
PeS
¼ 1
PtotalS
 1
PblankS
ð3Þ
PeS divided by the surface area (1 cm2 for Transwell-12) generated
the endothelial permeability coefﬁcient (Pe, 10–3 cm/min).
2.8. Analysis of levels of γ-glutamyl transpeptidase (γ-GT) and
alkaline phosphatase (ALP)
The levels of γ-GT and ALP were measured in the cells using the
commercially available assay kits. The kits were purchased from
Jiancheng Chemical Factory (Nanjing, China). hBMECs were
collected by scrapping and low-speed centrifugation (1000 rpm,
10 min) and measured according to manufacturer's protocols.
2.9. Statistical analysis
Data were expressed as mean7SEM and analyzed by one-way
analysis of variance (ANOVA) with LSD post-hoc correction used
for multiple comparisons in our experiment using Graph Pad Prism
version 4.0 (GraphPad Inc., La Jolla, USA). Values of Po0.05 are
considered statistically signiﬁcant and F values are given.3. Results
3.1. Quercetin increased cell viability against fAβ1–40-induced
toxicity in hBMECs
In this study, the protective effects of quercetin on hBMECs
against fAβ1–40-induced toxicity were investigated in three cyto-
toxicity assays. Firstly, we examined the effect of quercetin on cell
viability of hBMECs subjected to fAβ1–40 in the MTS assay. Cell
viability was found to be signiﬁcantly decreased in the presence of
20 μmol/L fAβ1–40 (Fig. 2A, Po0.001). Quercetin at 0.3 μmol/L,
3.0 μmol/L and 30.0 μmol/L dose-dependently increased cell
viability (Fig. 2A, Po0.05, Po0.001, Po0.001). Quercetin did
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fAβ1–40 injury at any of the evaluated concentrations.
The cytoprotective effects of quercetin were also demonstrated
by detecting LDH leakage caused by fAβ1–40. Treatment with
20 μmol/L fAβ1–40 led to signiﬁcant enzyme leakage from
hBMECs (Fig. 2B, Po0.001). However, when hBMECs were
treated with quercetin at 0.3 μmol/L, 3.0 μmol/L and 30.0 μmol/L
in the presence of fAβ1–40, the intensity of ﬂuorescence based on
the release of LDH in hBMECs decreased signiﬁcantly (Fig. 2B,
Po0.001). No obvious effects of quercetin on the release of LDH
from cells without fAβ1–40 at 0.3 μmol/L, 3.0 μmol/L and
30.0 μmol/L was found.
Similar effects were seen in the Hoechst 33342 staining assay.
Treatment with fAβ1–40 induced nuclear changes, indicating
heterogeneous intensities and chromatin condensation in the nuclei
of the fAβ1–40-injured hBMECs (Fig. 2C). These cytotoxic effects
were alleviated both in nuclear morphological condensation and
ﬂuorescence intensity through treatment with quercetin at
0.3 μmol/L, 3.0 μmol/L and 30.0 μmol/L in a dose-dependent
manner (Fig. 2D, Po0.05, Po0.001, Po0.001). Quercetin at
the same concentrations did not damage the nuclei of control cells.
Based on the above results, quercetin at 0.3 μmol/L, 3.0 μmol/L
and 30.0 μmol/L is found to signiﬁcantly increase the cell viability,
decrease LDH leakage, and ameliorate the nuclear injury induced
by fAβ1–40. Moreover, quercetin at the same concentrations did not
show any cytotoxicity. Summing up the above, we selected
concentrations ranging from 0.3 μmol/L to 30.0 μmol/L for further
investigation.Figure 2 Quercetin increased cell viability against fAβ1–40-induced toxic
MTS assay. n¼8, F (7, 56)¼9.541, Po0.001. (B) Quercetin decreased th
induced toxicity. n¼6, F (7, 40)¼24.144, Po0.001. (C) The representativ
the nuclear mean ﬂuorescence intensity in hBMECs against fAβ1–40-induc
mean7SEM, ***Po0.001 versus control group, #Po0.05, ##P o0.01, #3.2. Quercetin affected fAβ1–40-induced oxidative stress in
hBMECs
Oxidative stress plays an important role in Aβ-induced cytotoxi-
city. Therefore, we examined the effect of quercetin on fAβ1–40-
induced oxidative imbalance in hBMECs. The intracellular ROS
level of fAβ1–40-treated cells showed a remarkable increase
(Fig. 3A, Po0.001), while quercetin scavenged ROS generation
to protect cells at the concentrations of 0.3 μmol/L, 3.0 μmol/L and
30.0 μmol/L (Fig. 3A, Po0.01, Po0.001, Po0.001) in the
presence of fAβ1–40. The results also revealed that fAβ1–40
treatment induced the redox imbalance through decreasing SOD
activity (Fig. 3B, Po0.001). However, when the cells were treated
with quercetin at 0.3 μmol/L, 3.0 μmol/L and 30.0 μmol/L, SOD
activity was remarkably increased in a dose-dependent manner
(Fig. 3B, Po0.05, Po0.01, Po0.01).3.3. Quercetin improved barrier function of hBMECs against
fAβ1–40-induced toxicity
The BBB is a specialized barrier that maintains the integrity of
brain by restricting permeability across the brain endothelium. In
this study, the barrier integrity of BMECs and paracellular
permeability were determined by the measurement of TEER and
the ﬂux of ﬂuorescein sodium and FITC-albumin. As shown in
Fig. 4A, the values of TEER in fAβ1–40-treated cells were
signiﬁcantly reduced (Fig. 4A, Po0.001). Treatment withity in hBMECs. (A) Quercetin increased cell viability as evaluated by
e levels of extracellular LDH released from hBMECs against fAβ1–40-
e nuclear images stained with Hoechst 33342. (D) Quercetin inhibited
ed toxicity. n¼4, F (7, 24)¼11.761, Po0.001. Date are expressed as
##Po0.001 versus fAβ1–40 group.
Figure 3 Quercetin affected fAβ1–40-induced oxidative stress in hBMECs. (A) Quercetin decreased the generation of ROS in hBMECs in the
presence of fAβ1–40. n¼6, F (4, 25)¼45.616, Po0.001. (B) Quercetin improved the SOD activity in hBMECs against fAβ1–40-induced toxicity.
n¼4, F (4, 15)¼12.539, Po0.001. Date are expressed as mean7SEM, ***Po0.001 versus control group, #Po0.05, ##Po0.01, ###Po0.001
versus fAβ1–40 group.
Figure 4 Quercetin improved barrier function of hBMECs against fAβ1–40-induced toxicity. (A) Quercetin at concentrations of 3.0 μmol/L and
30.0 μmol/L decreased TEER. n¼4, F (4, 15)¼28.676, Po0.001. (B) Quercetin at concentration of 30.0 μmol/L decreased transendotheial
permeability for sodium ﬂuorescein. n¼4, F (4, 15)¼14.654, Po0.001. (C) Quercetin at concentrations of 3.0 μmol/L and 30 μmol/L decreased
FITC-albumin. n¼4, F (4, 15)¼13.999, Po0.001. Date are expressed as mean7SEM, **Po0.01, ***Po0.001 versus control group, #Po0.05,
##Po0.01, ###Po0.001 versus fAβ1–40 group.
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being exposed to fAβ1–40 at 3.0 μmol/L and 30.0 μmol/L (Fig. 4A,
Po0.01, Po0.001).
Permeability and paracellular diffusion across conﬂuent
hBMEC monolayers was then evaluated by measuring the perme-
ability coefﬁcient of the permeability markers, ﬂuorescein sodium
and FITC-albumin. In the fAβ1–40-treated groups, the Pe values
were both increased compared with the control group (Fig. 4B and C,
Po0.001, Po0.01). After co-treatment with fAβ1–40 and querce-
tin for 24 h, the Pe values of ﬂuorescein sodium and FITC-
albumin were both increased in the presence of 30.0 μmol/L
quercetin (Po0.05); meanwhile, the Pe value of FITC-albumin
was increased at 3.0 μmol/L quercetin as well (Po0.05).3.4. Quercetin modulated the levels of γ-GT and ALP in
fAβ1–40-treated hBMECs
γ-GT and ALP are known to be abundant in cerebral microvessels,
and the levels of these two enzymes are involved in barrier
formation. On the basis of the above results, we determined the
effect of the modulation of the levels of γ-GT and ALP in fAβ1–40-
treated hBMECs. Levels of γ-GT and ALP were signiﬁcantly
decreased in hBMECs after being exposed to fAβ1–40 (Fig. 5,
Po0.01, Po0.001), whereas quercetin reversed both changes at
3.0 μmol/L and 30.0 μmol/L (Fig. 5, Po0.01, Po0.01, Po0.001,
Po0.001). Moreover, quercetin at 0.3 μmol/L signiﬁcantly
increased ALP in presence of fAβ1–40, but not γ-GT.
Figure 5 Quercetin modulated levels of γ-GT and ALP in fAβ1–40-
treated hBMECs. Date are expressed as mean7SEM, n¼4. γ-GT: F
(4, 15)¼10.067, Po0.001; ALP: F (4, 15)¼28.919, Po0.001.
**Po0.01, ***Po0.001 versus control group, ## Po0.01, ###
Po0.001 versus fAβ1–40.
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The present study clariﬁes the beneﬁcial effects of quercetin on
AD-associated microvascular endothelial pathology. The present
ﬁndings indicate that quercetin can protect hBMECs from fAβ1–40-
induced toxicity. In these effects, quercetin increases cell viability,
reduces the amount of LDH release, relieves nuclear condensation,
decreases oxidative stress, and strengthens the barrier integrity and
functions through improving TEER, ameliorating transendotheial
permeability and modulating barrier enzyme levels. These results
suggest that quercetin protected endothelial cells against fAβ1–40-
induced endothelial dysfunction.
Recent advances in neuroscience research have contributed to
the emerging concept that the structural and functional integrity of
the central nervous system (CNS) depends on the coordinated
activity of the neurovascular unit. BMECs, known to be essential
for brain homeostasis, provide a dynamic interface between
circulating blood and the brain parenchyma1. Injuries to the
endothelial cells of blood vessels triggered by inﬂammation and
other insults (like Aβ) can result in endothelial death, which
contributes to the pathogenesis of diverse neurological disorders25.
Accordingly, results from experimental animal models and clinical
studies suggest that degenerative disorders are exacerbated, if not
initiated, by brain microvasculature injury. Therefore, effective
therapeutic strategies to protect neuronal functions, to preserve the
integrity of the BBB, and to ensure brain repair should also be
targeted toward the brain microvasculature.
Herein, we ﬁrstly evidenced that fAβ1–40 treatment causes
signiﬁcant cell injury in the hBMEC experimental system26. The
toxic effect of fAβ1–40 at 20 μmol/L was achieved in hBMECs,
involving decreasing cell viability, increasing LDH release, indu-
cing nuclear injury, overproducing intracellular ROS, reducing
SOD activity, and breaking the barrier function.
Appropriate administrative conditions for quercetin were deter-
mined using both control and fAβ1–40-injured hBMECs. Quercetin
at the determined optimal concentrations of 0.3 μmol/L, 3.0 μmol/L
and 30.0 μmol/L was found to signiﬁcantly increase the viability
of cells injured by fAβ1–40. In line with the increased viability, a
decrease in LDH release and relief of nuclear injury also indicated
the protective effects of quercetin in this process. In addition,
treatment of control cells with quercetin showed no statistically
signiﬁcant differences, indicating that quercetin has no toxicity
under basal conditions.Excessive generation of ROS within endothelial cells in
response to Aβ leads to oxidative stress and cellular injury27–29.
In vitro studies have revealed that oxidative stress results in
dysfunction of the endothelial cell, destroying the integrity of the
vascular barrier and leading to increased endothelial permeability,
mitochondrial dysfunction, chronic inﬂammatory processes and
amyloid deposition in blood vessels, which are involved in the
imbalance of endothelial transductions during the pathogenesis of
Alzheimer's deﬁcits30–32. Neuroprotective interventions for AD
should be effective in reducing the severity of oxidative injury and
maintaining the integrity of the BBB.
In this study an obvious imbalance was detected after treatment
with fAβ1–42 alone, involving a marked increase in ROS genera-
tion and a reduction of SOD activity. Treatment with quercetin
attenuated fAβ1–42-induced ROS generation and protected SOD
activity in hBMECs. Quercetin is a phenolic compound isolated
from plants, and has been thought to be effective in scavenging
free radicals33. Previous studies indicated that quercetin can act as
an antioxidant to protect the skin from oxidative stress induced by
ultraviolet rays34,35. Here, quercetin produced a signiﬁcant anti-
oxidant effect in hBMECs treated with fAβ1–40. We hypothesize
that quercetin might exert cytoprotective effects by suppressing
oxidative stress induced by Aβ18. Accumulating evidence suggests
that treatment with hydrogen peroxide disturbs the permeability
barrier of epithelial cells through disruption of tight junction
proteins36,37. As hydrogen peroxide is a member of ROS, we
suggest that quercetin protects hBMECs, at least in part, by
reducing the overproduction of ROS and improving anti-oxidant
efﬁcacy.
The restrictive nature of BMECs for forming the BBB is due to
tight junctions among adjacent endothelial cells. The BBB allows
for the regulation of ion ﬂux and paracellular diffusion through the
development of high transendothelial electrical resistance and tight
barrier properties38–40. The microvascular barrier function was
determined to be suitable for subsequent experiments, as shown by
the changes of TEER value, permeability property, and character-
istic enzymatic activity.
TEER value is an important indicator of the barrier tightness of
interendothelial tight junctions. In this study, the reduction of the
TEER value could be markedly attenuated by treatment with
quercetin at higher concentrations, indicating that the preservation
of monolayer integrity may contribute to its protective effects
against fAβ1–40-induced damage. In addition, quercetin treatment
at the highest concentrations attenuated apical-to-basolateral diffu-
sion of both ﬂuorescein sodium and FITC-albumin. Although
increased permeability can allow deleterious molecules into the
brain and aggravate the endothelial injury, it also may help
therapeutic agents cross the BBB. A relevant effect of quercetin
on the BBB function has been reported41, and the mechanisms
attributed to the Aβ25–35-induced toxicity in mice have been
suggested to result from suppression of MAPK transduction. In
combination with our studies, it provides evidence for the
explanation that quercetin can cross the BBB and has molecular
effects in the brain.
γ-GT and ALP are the important membranous components of
the BBB as well, known to be abundant on the apical surface of
microvascular endothelial cells41. The activities of these enzymes
can be altered in situations such as oxidative stress42, inﬂamma-
tion43 and hypoxia44. The levels of γ-GT and ALP changed
consistently with TEER value and barrier permeability when
subjected to fAβ1–40, and they could be preserved with the
quercetin treatment in a dose-dependent manner at 3.0 μmol/L
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of monolayer integrity based on TEER detection and transen-
dotheial permeability. Thus, we extrapolate that quercetin is
capable of protecting the barrier integrity and function of micro-
vascular endothelial monolayers treated with fAβ1–40.5. Conclusions
In summary, we have presented novel evidence to show that
quercetin effectively prevented fAβ1–40-induced hBMEC damage,
which was characterized by reduced cell viability, increased LDH
leakage and aggravated nuclear condensation. Furthermore, we found
that quercetin showed sufﬁcient activity in regulating the redox
imbalance and strengthening barrier integrity through the preserva-
tion of permeability and characteristic enzymatic activities in the
fAβ1–40-treated hBMECs. To our knowledge, this is the ﬁrst direct
evidence for an effect of quercetin on brain microvascular endothelial
cells. Our results provide a rational basis for the therapeutic
application of this compound in the prevention/treatment of AD.
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